AUDENTES THERAPEUTICS
Audentes Therapeutics doing business as Astellas Gene Therapies, Inc. is a biotechnology company that serves as the Gene Therapy Center of Excellence. The company is divided into three divisions that specialize in gene therapy research, including technical operations, medical and development, and future commercialization of gene therapy programs. Audentes Therapeutics was acquired by Astellas Pharma on January 15, 2020.
AUDENTES THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Health Diagnostics
Founded:
2013-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.audentestx.com
Total Employee:
251+
Status:
Active
Contact:
+1 (415) 638-6556
Email Addresses:
[email protected]
Total Funding:
744.7 M USD
Technology used in webpage:
Domain Not Resolving Euro SPF Google Tag Manager Amazon Global Site Tag IPv6 JsDelivr Microsoft Exchange Online Office 365 Mail
Similar Organizations
Alector
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Freenome
Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Geneoscopy
Geneoscopy develops a screening methodology to noninvasively diagnose colorectal cancer using biomarkers in stool samples.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Invitae
Invitae is a medical genetics company that bring comprehensive genetic information into mainstream medicine to improve healthcare.
Orchard Therapeutics
Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
PathAI
PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time.
Personalis
Personalis is a contract research organization and genome-scale diagnostics services company specializing in genome guided medicine.
Prenetics
Prenetics is a genetic and diagnostic health testing company that helps to identify health risks with the use of DNA sequencing technology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-09-01 | CardioGen Sciences | CardioGen Sciences acquired by Audentes Therapeutics | N/A |
Investors List
Envision Capital Management
Envision Capital Management investment in Post-IPO Equity - Audentes Therapeutics
Venrock
Venrock investment in Series C - Audentes Therapeutics
5AM Ventures
5AM Ventures investment in Series C - Audentes Therapeutics
Sofinnova Investments
Sofinnova Investments investment in Series C - Audentes Therapeutics
Deerfield
Deerfield investment in Series C - Audentes Therapeutics
Redmile Group
Redmile Group investment in Series C - Audentes Therapeutics
Asset Management Ventures (AMV)
Asset Management Ventures (AMV) investment in Series C - Audentes Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Audentes Therapeutics
OrbiMed
OrbiMed investment in Series C - Audentes Therapeutics
Foresite Capital
Foresite Capital investment in Series C - Audentes Therapeutics
Official Site Inspections
http://www.audentestx.com
- Host name: ec2-54-159-65-133.compute-1.amazonaws.com
- IP address: 54.159.65.133
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Audentes Therapeutics"
Audentes Therapeutics Information - RocketReach
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases.See details»
News - Astellas Pharma Inc. - Astellas Gene Therapies
Mar 31, 2021 Investor + Media Contacts: Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201 FAX: +81-3-5201-7473 Astellas Gene Therapies US Media Contact: Cassie …See details»
News - Astellas Pharma Inc. - Astellas Gene Therapies
TOKYO & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 2, 2019-- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Audentes Therapeutics, Inc. …See details»
AudentesTherapeutics - Company Profile - Tracxn
Dec 6, 2024 Developer of therapeutics to treat rare genetic diseases. The company's lead product AT845 is an adeno-associated virus (AAV) gene replacement therapy that delivers a …See details»
Astellas Completes Acquisition of Audentes Therapeutics
Jan 15, 2020 "The Audentes team is comprised of highly talented individuals with world-class expertise in AAV-based genetic medicines manufacturing, research and development, and …See details»
Audentes Therapeutics and Genethon Announce Agreement to …
Genethon, located in Evry, France, is a non-profit R&D organization dedicated to the development of biotherapeutics for orphan genetic diseases, from research to clinical validation. Genethon …See details»
Audentes Therapeutics - PitchBook
Audentes Therapeutics General Information Description. Operator of a biotechnology platform intended to offer gene therapy treatments for serious rare diseases. The company's platform …See details»
Dear Muscular Dystrophy Patient Community,
Www.audentestx.com April 8, 2019 Dear Muscular Dystrophy Patient Community, Today Audentes Therapeutics announced that it is expanding its scientific platform and beginning …See details»
Astellas Completes Acquisition of Audentes Therapeutics - PR …
Jan 15, 2020 Astellas Completes Acquisition of Audentes Therapeutics - Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to …See details»
Audentes Therapeutics Announces Co-Founder and Chief …
Oct 3, 2018 Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, ... please visit www.audentestx.com. Audentes Contacts: Investor …See details»
Audentes Therapeutics Board of Directors Appoints Co-Founder …
Nov 5, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products...See details»
REGENX Biosciences and Audentes Therapeutics Enter into …
For more information regarding Audentes, please visit www.audentestx.com. Contacts . REGENX Biosciences. Vit Vasista, 202-785-7438 [email protected]. or . Audentes Therapeutics, …See details»
Audentes Therapeutics | gene therapy - Versant Ventures
Audentes Therapeutics is committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases.See details»
Audentes Therapeutics Announces Expansion of AAV Technology …
Apr 8, 2019 This means that we are in the same part of the organization as other functions such as Medical Affairs and Clinical Development. The Head of the Patient Advocacy and …See details»
Astellas Enters into Definitive Agreement to Acquire Audentes ...
Dec 2, 2019 - Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company - Audentes to operate as an independent subsidiary, …See details»
Audentes Announces Positive Interim Data From First Dose
Jan 4, 2018 For more information regarding Audentes, please visit www.audentestx.com. About Genethon Genethon, located in Evry, France, is a non-profit R&D organization dedicated to …See details»
audentestx.net
Audentestx.netSee details»
Audentes Therapeutics and Genethon Announce Agreement to …
Feb 5, 2014 Audentes Therapeutics, Inc. Jeffrey Gruis, 415-638-6561 [email protected] or Genethon Gaëlle Monfort / Ellia Foucard-Tiab, + 33 1 69 47 28 59 / 25 64 …See details»
Log in to your Okta org
If you don’t have an Okta organization or credentials, use the Okta Digital Experience Account to get access to Learning Portal, Help Center, Certification, Okta.com, and much more.See details»